-
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
Latest News
-
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
⏱️6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of AMT-130 in the US.
-
TRACK-HD reveals changes in HD mutation carriers, empowering future trials
Follow-up data from TRACK-HD study proves that we have the tests we need to successfully run drug trials for HD
-
Huntexil hits the headlines again
Huntexil makes headlines with science journal article, but nothing's changed: another trial is needed before approval
-
New antibody reveals dangerous parts of huntingtin protein
A new antibody lets scientists identify neurons that are going to die after producing mutant huntingtin
-
Safety trials add crucial piece to gene silencing jigsaw
Three trials of drugs to 'silence' the HD gene in monkeys show they hit the target safely. Human trials coming soon.
-
Melatonin treatment success in HD mice
Melatonin delays disease onset and extends survival in Huntington's disease mice – could it do the same for patients?
-
HD World Congress 2011: a retrospective
HDBuzz looks back at the highlights of the Huntington's disease world congress 2011 in Melbourne
-
HDAC inhibitors and a possible 'blood biomarker'
HDAC inhibitors explained, plus how new HDAC-related Huntington's disease research might help us find biomarkers
-
HD just got cilia
Huntington's disease just got cilia: huntingtin protein affects tiny but important hairs on cells called cilia
-
Gene silencing takes a targeted step forward
Targeting the mutant Huntington's disease gene for silencing, while leaving the healthy gene untouched
-
Prana Biotech's new trial of PBT2 in Huntington's disease: the lowdown
Prana Biotech's PBT2 trial in Huntington's disease: what we know so far & what copper has to do with the mutant prote
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
